OTCMKTS:BSTG Biostage (BSTG) Stock Price, News & Analysis $4.45 0.00 (0.00%) As of 07/24/2023 Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Biostage Stock (OTCMKTS:BSTG) Get Biostage alerts:Sign Up Key Stats Today's Range$4.45▼$4.4550-Day Range$4.45▼$4.4552-Week Range$4.45▼$4.45VolumeN/AAverage Volume1,847 shsMarket Capitalization$61.77 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingBuy Company Overview Biostage, Inc. (OTCMKTS: BSTG) is a development‐stage regenerative medicine company dedicated to creating implantable, tissue‐engineered medical devices designed to treat severe organ disorders. The company’s proprietary platform integrates bioscaffolds with a patient’s own cells to produce living implants that can restore structure and function in damaged tissues. Biostage’s mission focuses on addressing unmet medical needs in life‐threatening conditions where conventional therapies offer limited efficacy. The company’s lead product candidate, the Neo‐Esophagus, is designed to replace or repair sections of the esophagus damaged by congenital defects, cancer resections, or severe trauma. Biostage also has earlier‐stage programs targeting airway reconstruction, leveraging the same scaffold‐and‐autologous‐cell technology. By using a patient’s own cells, the company aims to reduce the risk of rejection and eliminate the need for long‐term immunosuppression. Biostage has secured regulatory clearance to initiate clinical studies for its esophageal repair device and continues to advance its pipeline through preclinical development. Founded in 2003 under the name Tengion, the company rebranded as Biostage in 2018 to reflect its focus on true tissue regeneration and organ reconstruction. Headquartered in Cambridge, Massachusetts, Biostage operates within the United States, collaborating with research institutions and clinical investigators to drive its development programs forward. The company is led by a management team with extensive experience in biotechnology, medical devices, and regenerative medicine, positioning Biostage to translate its novel platform into potential therapies for patients with critical organ needs.AI Generated. May Contain Errors. Read More Biostage Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks2nd Percentile Overall ScoreBSTG MarketRank™: Biostage scored higher than 2% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.5 / 5Analyst RatingBuy Consensus RatingBiostage has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageBiostage has received no research coverage in the past 90 days.Read more about Biostage's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Biostage is -7.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biostage is -7.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for BSTG. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBiostage does not currently pay a dividend.Dividend GrowthBiostage does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Biostage this week, compared to 0 articles on an average week. Company Ownership0.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Biostage insiders have not sold or bought any company stock.Percentage Held by Insiders15.30% of the stock of Biostage is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsBiostage has minimal institutional ownership at this time.Read more about Biostage's insider trading history. Receive BSTG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biostage and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BSTG Stock News HeadlinesBiostage (OTCMKTS:BSTG) & Interpace Biosciences (OTCMKTS:IDXG) Financial ComparisonJune 30 at 6:25 AM | americanbankingnews.comBiostage stock initiated with Buy rating at TD Cowen on specialty growthJune 24, 2025 | investing.comCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to trigger the next crash. The research firm Bernstein Research said this AI company has the power to crash the global economy for a decade, the CEO just issued a CODE RED in an internal memo warning employees they're dealing with a critical situation, and another company executive even implied they might need a government bailout. The last time I saw something like this was in 2008 when I predicted a stock market meltdown just three weeks before Lehman went under.July 1 at 1:00 AM | Paradigm Press (Ad)Jefferies maintains Buy on Biostage shares with raised target amid bullish growth outlookJanuary 22, 2025 | msn.comHarvard Apparatus Regenerative Technology Inc (HRGN)January 5, 2024 | investing.comHRGN Harvard Apparatus Regenerative Technology Inc.August 22, 2023 | seekingalpha.comBiostage, Inc. Changes Name to Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN)July 20, 2023 | finance.yahoo.comBiostage Activated Mayo Clinic as The First Site for Clinical Trial in Severe Esophageal DiseaseJuly 18, 2023 | finance.yahoo.comSee More Headlines BSTG Stock Analysis - Frequently Asked Questions How have BSTG shares performed this year? Biostage's stock was trading at $4.45 at the beginning of 2026. Since then, BSTG stock has increased by 0.0% and is now trading at $4.45. How were Biostage's earnings last quarter? Biostage, Inc. (OTCMKTS:BSTG) issued its quarterly earnings results on Thursday, August, 13th. The company reported ($0.14) EPS for the quarter. How do I buy shares of Biostage? Shares of BSTG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Biostage own? Based on aggregate information from My MarketBeat watchlists, some other companies that Biostage investors own include Fulcrum Therapeutics (FULC), Ashford Hospitality Trust (AHT), Assertio (ASRT), Adaptimmune Therapeutics (ADAP), Akebia Therapeutics (AKBA). Company Calendar Last Earnings8/13/2020Today7/01/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolOTCMKTS:BSTG CIK1563665 Webwww.biostage.com Phone(744) 233-7300Fax774-233-7302Employees7Year Founded2012Profitability EPS (Trailing Twelve Months)($0.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$6.07 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-174.43% Debt Debt-to-Equity RatioN/A Current Ratio2.73 Quick Ratio2.73 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.26) per share Price / Book-17.12Miscellaneous Outstanding Shares13,882,000Free Float11,758,000Market Cap$61.77 million OptionableNot Optionable Beta-1.02 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (OTCMKTS:BSTG) was last updated on 7/1/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biostage, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biostage With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
